Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00059761 · ClinicalTrials.gov registry record · Phase 1

Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

A Phase 1 study, sponsored by Radiation Therapy Oncology Group.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target

NCT00059761 is a Phase 1 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 36 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00059761, a Phase 1 study, has completed, sponsored by Radiation Therapy Oncology Group.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effect on the body when combining irinotecan and cisplatin with radiation therapy in treating patients who have limited-stage small cell lung cancer that could not be completely removed during surgery.

Interventions

  • DRUG cisplatin
  • RADIATION radiation therapy
  • DRUG irinotecan hydrochloride

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2003-03
Est. Completion 2013-11
Phase Phase 1

Sponsor

Radiation Therapy Oncology Group

144 total trials

What the Registry Record Tells You About NCT00059761

The ClinicalTrials.gov registry entry for NCT00059761 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.

NCT00059761 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00059761 about?

NCT00059761 is a clinical study titled "Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effec...

What is the current status of trial NCT00059761?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2003-03. Estimated completion is 2013-11.

What interventions are being tested in trial NCT00059761?

The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), irinotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00059761?

This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.